Mylan N.V. (MYL): Price and Financial Metrics


Mylan N.V. (MYL)

Today's Latest Price: $14.82 USD

0.04 (0.27%)

Updated Sep 22 4:00pm

Add MYL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MYL Stock Summary

  • MYL has a market capitalization of $7,640,476,379 -- more than approximately 82.12% of US stocks.
  • Mylan NV's stock had its IPO on December 18, 1987, making it an older stock than 90.5% of US equities in our set.
  • Mylan NV's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.77%, greater than the shareholder yield of 84.76% of stocks in our set.
  • Stocks that are quantitatively similar to MYL, based on their financial statements, market capitalization, and price volatility, are PKI, AIN, HUN, CBT, and EBIX.
  • Visit MYL's SEC page to see the company's official filings. To visit the company's web site, go to www.mylan.com.
MYL Daily Price Range
MYL 52-Week Price Range

MYL Stock Price Chart Technical Analysis Charts


MYL Price/Volume Stats

Current price $14.82 52-week high $23.11
Prev. close $14.78 52-week low $12.75
Day low $14.48 Volume 5,311,106
Day high $14.95 Avg. volume 6,486,492
50-day MA $16.12 Dividend yield N/A
200-day MA $17.36 Market Cap 7.66B

Mylan N.V. (MYL) Company Bio


Mylan NV develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company was founded in 1961 and is based in Potters Bar, Hertfordshire.

MYL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$14.82$45.42 207%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Mylan NV. To summarize, we found that Mylan NV ranked in the 68th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 208.5%. The most interesting components of our discounted cash flow analysis for Mylan NV ended up being:

  • 39% of the company's capital comes from equity, which is greater than merely 19.33% of stocks in our cash flow based forecasting set.
  • Mylan NV's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 16.18% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Mylan NV has a reliance on debt greater than 87.75% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%201%
1%204%
2%207%
3%210%
4%213%
5%216%

SGRY, ALXN, LXRX, LCI, and HZNP can be thought of as valuation peers to MYL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


MYL Latest News Stream


Event/Time News Detail
Loading, please wait...

MYL Latest Social Stream


Loading social stream, please wait...

View Full MYL Social Stream

Latest MYL News From Around the Web

Below are the latest news stories about Mylan NV that investors may wish to consider to help them evaluate MYL as an investment opportunity.

Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Mylan (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the companies have received final approval from the European Commission (EC) for the proposed combination of Mylan and Pfizer Inc.'s Upjohn…

PR Newswire | September 15, 2020

Blueprint Receives FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation (BPMC) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is collaborating with Roche (RHHBY), and the drug will be commercialized in the United...

Avisol Capital Partners on Seeking Alpha | September 10, 2020

Mylan to Present at the BofA Securities Virtual Global Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury, together with President Rajiv Malik will present at the BofA Securities Virtual Global Healthcare Conference…

PR Newswire | September 9, 2020

S.African drugmaker Aspen sells thrombosis drug unit to Mylan

South African drugmaker Aspen Pharmacare said on Tuesday it had sold its European thrombosis business to U.S. pharmaceutical company Mylan for almost 642 million euros ($758.65 million).

Reuters Africa | September 8, 2020

Mylan and Biocon launch of Semglee in U.S.

Mylan N.V. (MYL) and Biocon Biologics India, a subsidiary of Biocon Ltd. (BCNQY), announce the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not...

Seeking Alpha | August 31, 2020

Read More 'MYL' Stories Here

MYL Price Returns

1-mo -9.25%
3-mo -9.52%
6-mo -0.40%
1-year -25.64%
3-year -52.65%
5-year -66.02%
YTD -26.27%
2019 -26.64%
2018 -35.24%
2017 10.90%
2016 -29.44%
2015 -4.08%

Continue Researching MYL

Here are a few links from around the web to help you further your research on Mylan NV's stock as an investment opportunity:

Mylan NV (MYL) Stock Price | Nasdaq
Mylan NV (MYL) Stock Quote, History and News - Yahoo Finance
Mylan NV (MYL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8251 seconds.